This $1,124,825 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to identify novel therapeutic targets for aggressive prostate cancer through induced pluripotent stem cell modeling of BRCA2 mutant prostate tissue. The award, which runs from August 1, 2024 to July 31, 2027, will enable UTHSCSA to conduct innovative scientific studies to advance understanding of aggressive prostate cancer and explore new treatment approaches. As an experienced federal grantee, UTHSCSA will leverage its expertise in areas like lipidomics, pathology, and statistical analysis to contribute specialized capabilities to this research initiative.